RDHL - RedHill Biopharma Ltd.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
6.23
+0.13 (+2.13%)
At close: 4:00PM EST

6.29 +0.06 (0.96%)
Pre-Market: 7:16AM EST

Stock chart is not supported by your current browser
Previous Close6.10
Open6.10
Bid0.00 x 800
Ask6.33 x 800
Day's Range6.06 - 6.28
52 Week Range5.13 - 9.20
Volume257,494
Avg. Volume209,823
Market Cap223.33M
Beta (3Y Monthly)0.50
PE Ratio (TTM)N/A
EPS (TTM)-1.47
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est21.88
  • GlobeNewswire

    RedHill Biopharma to Host Third Quarter 2019 Financial Results Conference Call on November 19, 2019

    TEL-AVIV, Israel and RALEIGH, N.C., Nov. 13, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the commercialization and development of proprietary drugs for the treatment of gastrointestinal diseases, today announced that it will report its third quarter 2019 financial results and operational highlights on Tuesday, November 19, 2019. The Company will host a conference call on Tuesday, November 19, 2019 at 8:30 a.m. EST to review the financial results and operational highlights. The conference call will be broadcast live and will be available for replay for 30 days on the Company's website, http://ir.redhillbio.com/events.

  • GlobeNewswire

    RedHill Biopharma Announces Publication of RHB-102 Gastroenteritis Phase 3 Study Results in JAMA

    TEL-AVIV, Israel and RALEIGH, N.C., Nov. 12, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the commercialization and development of proprietary drugs for the treatment of gastrointestinal diseases, today announced the publication of results from the Company’s Phase 3 study with RHB-102 (Bekinda®)1 in acute gastroenteritis (the GUARD study) in the Journal of the American Medical Association (JAMA) Network Open.

  • Triangle company builds workforce as it preps for commercialization
    American City Business Journals

    Triangle company builds workforce as it preps for commercialization

    A Triangle company's long-anticipated FDA approval has arrived, meaning the company is poised to start commercialization efforts it hopes will net a profit.

  • Reuters

    UPDATE 2-U.S. FDA approves RedHill's bacterial infection treatment

    RedHill Biopharma Ltd's said on Monday its three-drug combination therapy to treat Helicobacter pylori bacterial infections had been approved by the U.S. Food and Drug Administration, sending its shares up 25%. The drug, Talicia, is an oral capsule comprising two antibiotics, amoxicillin and rifabutin, as well as omeprazole, a common treatment for heartburn. The Israel-based company said the drug was designed to address the high resistance of H. pylori bacteria to current clarithromycin-based standard-of-care therapies.

  • Reuters

    U.S. FDA approves RedHill's H. pylori infection treatment

    The U.S. Food and Drug Administration has approved RedHill Biopharma Ltd's drug to treat infections caused by bacteria known as Helicobacter pylori, the Israel-based company said on Monday. RedHill expects to launch the drug, Talicia, in the United States in the first quarter next year. Helicobacter pylori infection affects over 50% of the population worldwide, according to Redhill, and is one of the strongest risk factor for the development of gastric cancer.

  • GlobeNewswire

    RedHill Biopharma Announces FDA Approval of Talicia® for Treatment of H. pylori in Adults

    TEL-AVIV, Israel and RALEIGH, N.C., Nov. 04, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of proprietary drugs for the treatment of gastrointestinal diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved Talicia® (omeprazole magnesium, amoxicillin and rifabutin) delayed-release capsules 10 mg1/250 mg/12.5 mg for the treatment of Helicobacter pylori (H. pylori) infection in adults. RedHill expects to launch Talicia in the U.S. in the first quarter of 2020 with its dedicated sales force.

  • Benzinga

    Attention Biotech Investors: Mark Your Calendar For These November PDUFA Dates

    The FDA worked overtime in October , deciding on the fate of several therapies and treatment options. Most reviews produced positive outcomes. Three new molecular entities, or NMEs, were approved in October, ...

  • GlobeNewswire

    RedHill Biopharma to Present at the BIO-Europe 2019 Conference

    TEL-AVIV, Israel and RALEIGH, N.C., Oct. 29, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of clinical late-stage, proprietary drugs for the treatment of gastrointestinal diseases, today announced that Mr. Adi Frish, Senior Vice President of Business Development and Licensing, will present a corporate overview at the BIO-Europe 2019 conference on Tuesday, November 12, 2019, at 2:30 p.m. CET, at the Hamburg Messe, Germany. A copy of Mr. Frish’s presentation will be available on the Company's website and may be viewed at: http://ir.redhillbio.com. RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) is a specialty biopharmaceutical company, primarily focused on the development and commercialization of clinical late-stage, proprietary drugs for the treatment of gastrointestinal diseases.

  • GlobeNewswire

    RedHill Biopharma to Present New Phase 3 Data on RHB-105 and RHB-104 at the American College of Gastroenterology 2019 Annual Meeting

    TEL-AVIV, Israel and RALEIGH, N.C., Oct. 28, 2019 -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty.

  • Benzinga

    The Week Ahead In Biotech: Adcom Test For Agile; Pfizer, Merck Lead Earnings

    Earnings, clinical trial readouts and positive FDA verdicts catalyzed fairly robust performances by biotech stocks last week. Biogen Inc  (NASDAQ: BIIB )'s  about-face with respect to its Alzheimer's drug ...

  • Triangle drugmaker lands $36M deal with Ireland-based pharma
    American City Business Journals

    Triangle drugmaker lands $36M deal with Ireland-based pharma

    On the eve of a Triangle drugmaker's approval for its lead candidate, it has struck a deal with a major pharmaceutical company for $36 million and rights to a new drug – selling off about 20 percent of its stock in the deal.

  • GlobeNewswire

    RedHill Biopharma Announces $36 Million Strategic Investment by Cosmo Pharmaceuticals and U.S. Rights to Approved Travelers’ Diarrhea Drug AEMCOLO

    TEL-AVIV, Israel and RALEIGH, N.C., Oct. 18, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of clinical late-stage, proprietary drugs for the treatment of gastrointestinal diseases, today announced that it has entered into a strategic collaboration with Cosmo Pharmaceuticals N.V. (SIX:COPN) (“Cosmo”). The strategic collaboration includes an exclusive license agreement for the U.S. rights to Aemcolo® (rifamycin) and a simultaneous private investment by Cosmo of $36.3 million in RedHill at $7.00 per American Depositary Share (ADS), representing approximately 13.5% over the closing price on October 17, 2019, with a 180-day transfer restriction.

  • GlobeNewswire

    RedHill Biopharma Sponsors No Stomach For Cancer’s Symposium Ahead of Stomach Cancer Awareness Month

    TEL-AVIV, Israel and RALEIGH, N.C., Oct. 16, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of clinical late-stage, proprietary drugs for the treatment of gastrointestinal diseases, today announced its support of a number of prevention and awareness initiatives for Stomach Cancer Awareness Month, including its sponsorship of the No Stomach For Cancer’s (NSFC) Spotlight on Stomach Cancer Symposium. The symposium will take place on Saturday, October 26, 2019, from 8 a.m. - 2 p.m. MST at the University of Arizona in Tucson, Arizona.

  • GlobeNewswire

    RedHill Biopharma Announces Full Results from Positive MAP US Phase 3 Study and Supportive Top-Line Results from MAP US2 Open-Label Extension Study with RHB-104 in Crohn’s Disease

    TEL-AVIV, Israel and RALEIGH, N.C., Oct. 11, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of clinical late-stage, proprietary drugs for the treatment of gastrointestinal diseases, today announced  full Week 52 results for all subjects in the previously announced positive Phase 3 randomized, controlled study of RHB-104 in Crohn’s disease (the “MAP US study”) and supportive top-line results from the open-label extension Phase 3 study (the “MAP US2 study”). The full Week 52 results of blinded treatment in the MAP US Phase 3 study with RHB-104 were consistent with the previously reported positive outcomes of the study.

  • GlobeNewswire

    RedHill Biopharma Provides H2/2019 R&D Update

    TEL-AVIV, Israel and RALEIGH, N.C., Sept. 26, 2019 -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty.

  • GlobeNewswire

    RedHill Biopharma to Present at Upcoming Investor Conferences in September

    TEL-AVIV, Israel and RALEIGH, N.C., Aug. 27, 2019 -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty.

  • GlobeNewswire

    RedHill Biopharma Announces Acceptance of Oral Presentations on RHB-105 (H. pylori) and RHB-104 (Crohn’s Disease) Phase 3 Data at ACG 2019 Annual Scientific Meeting

    TEL-AVIV, Israel and RALEIGH, N.C., Aug. 21, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of clinical late-stage, proprietary drugs for the treatment of gastrointestinal diseases, today announced that it will present data from the positive Phase 3 clinical studies of RHB-105 (Talicia®)1 for H. pylori infection and RHB-104 for Crohn’s disease at the upcoming American College of Gastroenterology (ACG) 2019 Annual Scientific Meeting (October 25-30, 2019). In addition, an oral presentation on RHB-105 (Talicia) was also accepted for presentation at the XXXIInd International Workshop on Helicobacter & Microbiota in Inflammation and Cancer of the European Helicobacter and Microbiota Study Group (EHMSG 2019) (September 5-7, 2019).

  • GlobeNewswire

    RedHill Biopharma Reports Second Quarter 2019 Financial Results and Operational Highlights

    Key Highlights and Upcoming Milestones: U.S. FDA acceptance of the New Drug Application (NDA) for Talicia® for H. pylori for priority review and assignment of a target PDUFA.

  • ACCESSWIRE

    RedHill Biopharma Ltd. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / July 23, 2019 / RedHill Biopharma Ltd. (NASDAQ: RDHL ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on July 23, 2019 at 8:30 AM ...

  • 3 Small-Caps That Look Like Bargains at Current Trading Levels
    TheStreet.com

    3 Small-Caps That Look Like Bargains at Current Trading Levels

    No resolution seems on the horizon on the U.S.-China trade front as both sides have dug in their heels. Since the end of February the S&P 500 has continued to advance despite a pullback in May, while the Russell 2000 has stalled out. Let's look at three small-caps that seem like good bargains at current trading levels, starting with BioDelivery Sciences International Inc. .

  • GlobeNewswire

    RedHill Biopharma to Host Second Quarter 2019 Financial Results Conference Call on July 23, 2019

    TEL-AVIV, Israel and RALEIGH, N.C., July 15, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of clinical late-stage, proprietary drugs for the treatment of gastrointestinal diseases, today announced that it will report its second quarter 2019 financial results and operational highlights on Tuesday, July 23, 2019. The Company will host a conference call on Tuesday, July 23, 2019 at 8:30 a.m. EDT to review the second quarter 2019 financial results and operational highlights. The conference call will be broadcast live and will be available for replay for 30 days on the Company's website, http://ir.redhillbio.com/events.

  • 3 Biotech Stocks That Could Double Your Money
    Motley Fool

    3 Biotech Stocks That Could Double Your Money

    Here's what you need to know about the upgrades and bullish price targets analysts recently slapped on these drugmakers.

  • GlobeNewswire

    RedHill Biopharma Announces FDA Acceptance of New Drug Application for Talicia®

    TEL-AVIV, Israel and RALEIGH, N.C., July 03, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on gastrointestinal diseases, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for Talicia® (RHB-105)1 for H. pylori infection. The NDA for Talicia has also been granted Priority Review designation and was assigned a target Prescription Drug User Act (PDUFA) action date by the FDA of November 2, 2019.

  • GlobeNewswire

    RedHill Biopharma Receives Allowance for New U.S. Patent Covering RHB-104 for Crohn’s Disease and RHB-204 for NTM Infections

    TEL-AVIV, Israel and RALEIGH, N.C., June 10, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on gastrointestinal diseases, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a new patent covering RHB-104 for Crohn’s disease and RHB-204 for Mycobacterium avium complex (MAC) disease, the most common cause of pulmonary nontuberculous mycobacteria (NTM) infections1. Once granted, the patent is expected to be valid until at least 2029.